Testing bone marrow and blood in children with relapsed or hard-to-treat leukemia
Examines bone marrow and blood samples from young people with leukemia that returned.
Plain-language title generated from the registry record
Registry title: The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Key facts
- Where
- Parkville, Perth, South Brisbane, and Westmead, AustraliaSee the 4 sites
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children, teens and young adults under 22 whose leukemia or related blood disease has come back or did not respond to treatment. Blood and bone marrow are tested to find a fitting study.
- Age
- Under 22 years
- Sex
- All sexes can join
- Disease stage
- Known or suspected relapsed or hard-to-treat (refractory) acute myeloid leukemia (AML), myeloid leukemia of Down syndrome, mixed phenotype acute leukemia (MPAL), or juvenile myelomonocytic leukemia (JMML). Also relapsed B-ALL or T-ALL as defined in the protocol, and new or relapsed treatment-related AML, myelodysplastic syndrome (MDS) or treatment-related MDS.
- Biomarker or test result
- For B-ALL: a second or later relapse in the bone marrow, not counting KMT2Ar. Or any first or later B-ALL bone marrow relapse involving KMT2Ar. For T-ALL: any first or later bone marrow relapse, with or without KMT2Ar.
Read by machine on 9 November 2026.
Where in Australia
- Royal Children's HospitalParkville, AustraliaTaking people
- Perth Children's HospitalPerth, AustraliaTaking people
- Queensland Children's HospitalSouth Brisbane, AustraliaTaking people
- The Children's Hospital at WestmeadWestmead, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- PedAL BCU, LLC
- Trial code
- NCT04726241
- Record updated
- 25 August 2026
- Original description
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.Read full original descriptionShow less
Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.
Inclusion: Patients must be less than 22 years of age at the time of study enrollment; Patient must have one of the following at the time of study enrollment:; Patient has known or suspected relapsed/refractory (including primary refractory) AML as defined in protocol; This includes isolated myeloid sarcoma; Patient has known or suspected relapsed/refractory (including primary refractory) myeloid leukemia of Down syndrome (ML-DS); Patient has known or suspected relapsed ALL as defined in protocol that meets one of the following criteria:; Second or greater B-ALL medullary relapse, excluding KMT2Ar; Any first or greater B-ALL medullary relapse involving KMT2Ar; Any first or greater T-ALL medullary relapse with or without KMT2Ar; Patient has known or suspected relapsed/refractory (including primary refractory) mixed phenotype acute leukemia (MPAL) as defined in protocol; Patient has known or suspected de novo or relapsed/refractory (including primary refractory) treatment-related AML (t-AML); Patient has known or suspected de novo or relapsed/refractory (including primary refractory) myelodysplastic syndrome (MDS) or treatment-related myelodysplastic syndrome (t-MDS); Note: Relapsed/refractory disease includes stable disease, progressive disease, and disease relapse; Patient has known or suspected de novo or relapsed/refractory (including primary refractory) juvenile myelomonocytic leukemia (JMML); Note: Relapsed/refractory disease includes stable disease, progressive disease, and disease relapse; All patients and/or their parents or legal guardians must sign a written informed consent; All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met.